BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31585624)

  • 1. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.
    Martinez XU; Di Raimondo C; Abdulla FR; Zain J; Rosen ST; Querfeld C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):239-252. PubMed ID: 31585624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.
    Horna P; Moscinski LC; Sokol L; Shao H
    Cytometry B Clin Cytom; 2019 May; 96(3):234-241. PubMed ID: 30328260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mycosis fungoides and Sézary syndrome : a systematic review].
    André F; Guenova E; Blanchard G
    Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycosis fungoides and Sézary syndrome.
    Jonak C; Tittes J; Brunner PM; Guenova E
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycosis Fungoides and Sézary Syndrome: An Update.
    Larocca C; Kupper T
    Hematol Oncol Clin North Am; 2019 Feb; 33(1):103-120. PubMed ID: 30497668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycosis fungoides and the Sézary syndrome.
    Kim YH; Hoppe RT
    Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
    Sethi TK; Montanari F; Foss F; Reddy N
    Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome.
    Jiang TT; Cao S; Kruglov O; Virmani A; Geskin LJ; Falo LD; Akilov OE
    J Invest Dermatol; 2024 May; 144(5):1088-1098. PubMed ID: 38036289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants.
    Edelson RL
    J Am Acad Dermatol; 1980 Feb; 2(2):89-106. PubMed ID: 6988470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycosis fungoides and sezary syndrome: an update.
    Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
    Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
    Hristov AC; Tejasvi T; Wilcox RA
    Am J Hematol; 2023 Jan; 98(1):193-209. PubMed ID: 36226409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management.
    Hristov AC; Tejasvi T; Wilcox RA
    Am J Hematol; 2019 Sep; 94(9):1027-1041. PubMed ID: 31313347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous T-cell lymphoma-Focus on some problems, and some solutions.
    Beltraminelli H
    Hematol Oncol; 2023 Jun; 41 Suppl 1():20-24. PubMed ID: 37294972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
    Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides.
    Cetinözman F; Jansen PM; Vermeer MH; Willemze R
    Arch Dermatol; 2012 Dec; 148(12):1379-85. PubMed ID: 23247480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.